BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38372058)

  • 1. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
    Christopoulos P
    Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
    West HJ; Kim JY
    JAMA Oncol; 2024 Feb; 10(2):249-255. PubMed ID: 38153722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
    Heymach JV; Mitsudomi T; Harpole D; Aperghis M; Jones S; Mann H; Fouad TM; Reck M
    Clin Lung Cancer; 2022 May; 23(3):e247-e251. PubMed ID: 34819266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
    Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY
    Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
    Chen LN; Wei AZ; Shu CA
    Ther Adv Med Oncol; 2023; 15():17588359231163798. PubMed ID: 37007633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
    Dunne EG; Fick CN; Isbell JM; Chaft JE; Altorki N; Park BJ; Spicer J; Forde PM; Gomez D; Iyengar P; Harpole DH; Stinchcombe TE; Liberman M; Bott MJ; Adusumilli PS; Huang J; Rocco G; Jones DR
    Ann Thorac Surg; 2024 Feb; ():. PubMed ID: 38316378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?
    Collazo-Lorduy A; Blanco M; Calvo V; Provencio M
    Curr Opin Pulm Med; 2024 Jul; 30(4):346-351. PubMed ID: 38712693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
    Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease.
    Sathiyapalan A; Baloush Z; Ellis PM
    Curr Oncol; 2023 Oct; 30(11):9514-9529. PubMed ID: 37999109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
    Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review.
    Blakely CM; Weder W; Bubendorf L; He J; Majem M; Shyr Y; Chaft JE
    Lung Cancer; 2023 Mar; 177():59-72. PubMed ID: 36736076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
    Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
    J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions.
    Saw SP; Ang MK; Tan DS
    Curr Treat Options Oncol; 2022 Dec; 23(12):1721-1731. PubMed ID: 36451063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
    Lee JM; Tsuboi M; Brunelli A
    Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
    Leonetti A; Minari R; Boni L; Gnetti L; Verzè M; Ventura L; Musini L; Tognetto M; Tiseo M
    Clin Lung Cancer; 2021 Sep; 22(5):473-477. PubMed ID: 33762169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Perioperative Immunotherapies in Lung Cancer.
    Fukuda S; Suda K; Hamada A; Tsutani Y
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.
    de Scordilli M; Michelotti A; Bertoli E; De Carlo E; Del Conte A; Bearz A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
    Zhai H; Zhong W; Yang X; Wu YL
    Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.